Publications 2020

Ryg U, Lilleby W, Hole KH, Lund-Iversen M, Switlyk MD (2020)
Local Recurrence of Prostate Cancer to the Intersphincteric Space: A Case Report
Urology, 140, 18-21
DOI 10.1016/j.urology.2020.03.009, PubMed 32199872

Thorsen L, Haugnes HS, Fosså SD, Brydøy M, Tandstad T, Wisløff T, Gjerset GM, Edvardsen E, Larsen KO, Sandset PM, Henriksson CE, Raastad T, Negaard HFS (2020)
Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature
Int J Cancer (in press)
DOI 10.1002/ijc.33151, PubMed 32525564

Publications 2019

Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S, Global Germ-Cell Cancer Group (2019)
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
J Clin Oncol, 38 (12), 1322-1331
DOI 10.1200/JCO.19.01876, PubMed 31877087

Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2019)
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol, 3 (3), 382-389
DOI 10.1016/j.euo.2019.08.002, PubMed 31506250

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS (2019)
Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era
Int J Cancer, 147 (1), 21-32
DOI 10.1002/ijc.32704, PubMed 31597192

Lilleby O, Hernes E, Lilleby W (2019)
Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
Urol Case Rep, 27, 100992
DOI 10.1016/j.eucr.2019.100992, PubMed 31453108

Rud E, Langberg CW, Baco E, Lauritzen P, Sandbæk G (2019)
MRI in the Follow-up of Testicular Cancer: Less is More
Anticancer Res, 39 (6), 2963-2968
DOI 10.21873/anticanres.13427, PubMed 31177136

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2019)
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
Eur Urol, 77 (1), 3-10
DOI 10.1016/j.eururo.2019.03.022, PubMed 30992160

Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2019)
A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy
Asian J Urol, 7 (2), 161-169
DOI 10.1016/j.ajur.2019.08.001, PubMed 32257809

Switlyk MD, Salberg UB, Geier OM, Vlatkovic L, Lilleby W, Lyng H, Seierstad T (2019)
PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings
AJR Am J Roentgenol, 212 (6), 1206-1214
DOI 10.2214/AJR.18.20743, PubMed 30888866

Publications 2018

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L, Investigators of the Scandinavian Prostate Cancer Study Number 12 (2018)
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
Eur Urol, 73 (6), 870-876
DOI 10.1016/j.eururo.2018.01.012, PubMed 29395502

Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M (2018)
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol, 37 (4), 289.e19-289.e26
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV et al. (2018)
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
JAMA, 319 (9), 896-905
DOI 10.1001/jama.2018.0587, PubMed 29509865

Rogg L (2018)
NO MAN'S LAND For those who did not die, who are no longer sick, nor are they healthy
Tidsskr. Nor. Laegeforen., 138 (5), 483

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2018)
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Int J Radiat Oncol Biol Phys, 101 (4), 883-888
DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O (2018)
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
Scand J Urol, 52 (5-6), 313-320
DOI 10.1080/21681805.2018.1520295, PubMed 30585526

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 60 (8), 1028-1038
DOI 10.1177/0284185118810977, PubMed 30379559

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A (2018)
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Eur J Cancer, 97, 33-40
DOI 10.1016/j.ejca.2018.03.007, PubMed 29685343

Publications 2017

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Publications 2016

Lilleby W, Stensvold A, Dahl AA (2016)
Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer
Acta Oncol, 55 (7), 807-13
DOI 10.3109/0284186X.2015.1127417, PubMed 26959297

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G, SWENOTECA (2016)
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
Ann Oncol, 27 (7), 1299-304
DOI 10.1093/annonc/mdw164, PubMed 27052649

Publications 2015

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452

Lilleby W, Raabe NK, Normann M (2015)
[Re: The problematical prostate cancer]
Tidsskr Nor Laegeforen, 135 (11), 1009
DOI 10.4045/tidsskr.15.0593, PubMed 26080763

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015)
Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy
Acta Oncol, 54 (10), 1805-13
DOI 10.3109/0284186X.2015.1037008, PubMed 25927504

Rogg LV (2015)
Medical humanities companion, vol 4, Prognosis
Tidsskr. Nor. Laegeforen., 135 (4), 358

Raabe NK, Normann M, Lilleby W (2015)
Low-dose-rate brachytherapy for low-grade prostate cancer
Tidsskr Nor Laegeforen, 135 (6), 548-52
DOI 10.4045/tidsskr.13.1404, PubMed 25806763

Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A (2015)
[Re: Different guidelines for treatment of prostate cancer]
Tidsskr Nor Laegeforen, 135 (12-13), 1105
DOI 10.4045/tidsskr.15.0652, PubMed 26130530

Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD (2015)
Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients
Clin Genitourin Cancer, 14 (3), e265-73
DOI 10.1016/j.clgc.2015.10.009, PubMed 26778476

Publications 2014

Lilleby W, Stensvold A, Dahl AA (2014)
Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up
Acta Oncol, 53 (10), 1380-9
DOI 10.3109/0284186X.2014.916042, PubMed 24844918

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD (2014)
Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment
Clin Genitourin Cancer, 12 (4), e117-25
DOI 10.1016/j.clgc.2013.12.007, PubMed 24524968

Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G, SWENOTECA (2014)
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
Ann Oncol, 25 (11), 2167-72
DOI 10.1093/annonc/mdu375, PubMed 25114021

Publications 2013

Lilleby W, Stensvold A, Dahl AA (2013)
Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life
Prostate, 73 (10), 1038-47
DOI 10.1002/pros.22651, PubMed 23532709

Publications 2011

Lilleby W, Tafjord G, Raabe NK (2011)
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
Int J Radiat Oncol Biol Phys, 83 (3), 933-9
DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456

Lilleby W, Willoch F, Stensvold A (2011)
Detection of prostate cancer relapse with PET/CT using a novel radiotracer
Acta Oncol, 51 (3), 397-9
DOI 10.3109/0284186X.2011.614638, PubMed 21936756

Wedde TB, Lobmaier IV, Brennhovd B, Lohne F, Hall KS (2011)
Primary Ewing's Sarcoma of the Kidney in a 73-Year-Old Man
Sarcoma, 2011, 978319
DOI 10.1155/2011/978319, PubMed 21776194

Publications 2010

Rogg L, Aasland OG, Graugaard PK, Loge JH (2010)
Direct communication, the unquestionable ideal? Oncologists' accounts of communication of bleak prognoses
Psychooncology, 19 (11), 1221-8
DOI 10.1002/pon.1691, PubMed 20186873

Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2010)
A prospective study of neuropsychological functioning in testicular cancer patients
Ann Oncol, 22 (5), 1062-1070
DOI 10.1093/annonc/mdq553, PubMed 21048038

Publications 2009

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
DOI 10.4045/tidsskr.08.0649, PubMed 19247406

Rogg L, Loge JH, Aasland OG, Graugaard PK (2009)
Physicians' attitudes towards disclosure of prognostic information: a survey among a representative cross-section of 1605 Norwegian physicians
Patient Educ Couns, 77 (2), 242-7
DOI 10.1016/j.pec.2009.03.007, PubMed 19356882

Publications 2007

Lilleby W (2007)
Use of bisphosphonates in advanced prostate cancer: Current status
Indian J Urol, 23 (1), 54
DOI 10.4103/0970-1591.30268, PubMed 19675764

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2006

Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
[Treatment of hormone-resistant prostate cancer]
Tidsskr Nor Laegeforen, 126 (21), 2798-801
PubMed 17086220

Rogg L, Graugaard PK, Loge JH (2006)
Physicians' interpretation of the prognostic term "terminal": a survey among Norwegian physicians
Palliat Support Care, 4 (3), 273-8
DOI 10.1017/s1478951506060342, PubMed 17066968

Publications 2005

Lilleby W, Sudbø J, Fosså SD (2005)
[Biology and treatment options during the development of prostate cancer]
Tidsskr Nor Laegeforen, 125 (5), 571-4
PubMed 15776028

Publications 2003

Lilleby W, Dale E, Olsen DR, Gude U, Fosså SD (2003)
Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose
Acta Oncol, 42 (1), 10-4
DOI 10.1080/0891060310002177, PubMed 12665325

Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
Int J Cancer, 103 (1), 91-6
DOI 10.1002/ijc.10780, PubMed 12455058

Publications 2001

Lilleby W, Paus E, Skovlund E, Fosså SD (2001)
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
Prostate, 46 (2), 126-33
DOI 10.1002/1097-0045(20010201)46:2<126::aid-pros1016>3.0.co;2-7, PubMed 11170140

Lilleby W, Torlakovic G, Torlakovic E, Skovlund E, Fosså SD (2001)
Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy
Cancer, 92 (2), 311-9
DOI 10.1002/1097-0142(20010715)92:2<311::aid-cncr1324>3.0.co;2-h, PubMed 11466684

Publications 2000

Lilleby W, Fosså SD, Knutsen BH, Abildgaard A, Skovlund E, Lien HH (2000)
Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation
Radiother Oncol, 57 (2), 195-200
DOI 10.1016/s0167-8140(00)00219-x, PubMed 11054523

Publications 1999

Lilleby W, Fosså SD, Waehre HR, Olsen DR (1999)
Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy
Int J Radiat Oncol Biol Phys, 43 (4), 735-43
DOI 10.1016/s0360-3016(98)00475-1, PubMed 10098428

Lilleby W, Olsen DR, Foss a SD (1999)
Comparison of radiation side-effects in prostate cancer
Lancet, 353 (9162), 1443
DOI 10.1016/s0140-6736(05)75969-9, PubMed 10227249

Publications 1984

Langberg CW, Barkve H, Tjørstad K (1984)
[Cryptococcus neoformans meningoencephalitis]
Tidsskr Nor Laegeforen, 104 (14), 968-70
PubMed 6087494

 
Page visits: 631